The Directory of Pharma Companies and News


Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology. The shortcomings of current CAR treatment include a lack of selective tumour targeting mechanisms, serious side-effects associated with efficacy and the inability to overcome the hostile solid tumour microenvironment. Autolus is developing T-cell products incorporating technology components designed to overcome these shortcomings and to allow programmable CAR T-cell activity tailored for specific clinical situations. It is expected that this platform will provide a source of sustainable competitive advantage in both haematological and solid cancers, most of which are not addressable using the current CAR technology. Autolus’ shareholders include Syncona LLP and UCL Business PLC.

Autolus News

Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.